Russell Hirsch
Managing Director @ Prospect Venture Partners
Atlantic City, United States
Russell Hirsch is a seed investor at Prospect Venture Partners in Atlantic City focused on Health Care and Medical. Russell is a Managing Director of Prospect Venture Partners. Russell co-founded Prospect Venture Partners II and III, as dedicated life science funds with over $1 billion in capital under management. Prior to establishing Prospect Venture Partners II and III, Russell was a member of the Health Care Technology Group at Mayfield. He joined Mayfieldin 1992, served as a Venture Partner from 1993 to 1994 and as a General Partner from 1995-2000. Russell played a key role in Mayfield's investment activities in the biotechnology and medical device sectors. As an Associate, he participated actively in the incubation of Millennium Pharmaceuticals and as a General Partner he was responsible for the incubation of Intuitive Surgical Devices both of which are now publicly traded. (NASDAQ: MLNM), (NASDAQ:ISRG).Prior to Mayfield, Russell was at the University of California San Francisco from 1984-1992 where he was engaged in biomedical research. His work, published in a variety of respected journals, focused on important aspects of hepatitis B viral replication. His descriptions of the reverse transcription and packaging functions of polymerase gene products merited publication in Nature.Russell serves or has served on the Board of Directors of Intuitive Surgical (NASDAQ: ISRG), Hansen Medical (NASDAQ: HNSN), Opus Medical (NASDAQ: ARTC), Orquest (NASDAQ: JNJ), AVEO Pharmaceuticals, Visiogen, Baxano, Dfine, Allux Medical, SentreHEART, Portola Pharmaceuticals and several other privately-held companies. Russell serves as the Vice Chairman of the BOD of Interplast and on the Genetics Advisory Council of the Harvard Medical School-Partners Healthcare Center for Genetics and Genomics.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 36%
Last updated:
For AI agents: llms.txt
Industries Russell Hirsch invests in
Stages Russell Hirsch invests in
Countries Russell Hirsch invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Series A
- $7.3M–$33M
Investment Focus
Industry
- Health Care 5 (45%)
- Medical 3 (27%)
- Software 2 (18%)
- SaaS 1 (9%)
- Social 1 (9%)
Stage
- Seed 3 (27%)
- Series A 3 (27%)
- Pre-Seed 1 (9%)
- Series B 1 (9%)
- Series C 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Sholder, short for Spaceholder™, is a new standard in non-clinical mental & emotional health, powered by compassionate, skilled people from communities like yours. We provide high-affinity, one-to-one emotional support for employees in industries with heavy emotional demand and high burnout rates. | Pre-Seed / Jun 30, 2022 | ||
| datma is a technology begins with hyperefficient data storage and aggregation solutions for genomic imaging, and other healthcare datasets. We couple this with best-in-class, fully customizable data visualization to ensure clinicians and researchers get the data and insights they need exactly when and how they need them. Findings that areindividually rare may be collectively common. dātma’s solutions for secure data federation ensure that healthcare data stay securely in the data owner’s tenancy while facilitating networked analysis and discovery. | $4M / Venture - Series Unknown / Jun 15, 2022 | ||
| Third Eye Health is a national healthcare company providing high quality telehealth to post-acute and senior care organizations. They empower these organizations to reduce hospital readmissions and provide higher acuity care. It is reimagined post acute care delivered by specially trained physicians using simple but powerful technology. | $7.3M / Series A / Feb 18, 2019 | ||
| Enwoven empowers organizations to combine important assets and context together in the form of dynamic narratives and flexible knowledge bases. Companies create valuable ideas, thoughts and insights that get lost everyday.We work with brands like the NY Times, Coca-Cola, Reebok, Campbell's, Avis, and Procter & Gamble to help themdocument brand history, marketing campaigns, innovation, important initiatives, company culture and much more. | Seed / Nov 04, 2015 | ||
| NinePoint Medical, Inc. is a transformational medical device company developing innovative, real-time, in vivo pathology devices. The company's first goal is to develop a device that enables remote pathology, or telepathology, which would facilitate immediate review of images during diagnostic procedures. This capability could potentiallyprovide physicians with immediately actionable information and eventually allow them to pursue therapeutic remedies at the time of diagnosis. This convergence of access, diagnosis and treatment during one procedure is expected to improve patient experiences and outcomes, improve the efficiency of care and provide important savings to the healthcare system. Headquartered in Cambridge, Mass., NinePoint is backed by Third Rock Ventures and Prospect Venture Partners. | $34M / Series B / Mar 18, 2014 | ||
| Glooko is the universal diabetes platform that provides insights to improve outcomes for people with diabetes (PWDs) and their care teams. Glooko connects to the world’s most popular diabetes devices, major fitness and activity trackers and supplies personalized, timely patient information such as glucose level, food, insulin, medications, bloodpressure, diet and weight data. Trusted by the world’s leaders in diabetes care, we are in over 7,000 clinical locations and used by over 1.5 million PWDs in 23 countries across 15 languages. Learn more by visiting www.glooko.com. | $1M / Seed / Nov 10, 2011 | ||
| NinePoint Medical, Inc. is a transformational medical device company developing innovative, real-time, in vivo pathology devices. The company's first goal is to develop a device that enables remote pathology, or telepathology, which would facilitate immediate review of images during diagnostic procedures. This capability could potentiallyprovide physicians with immediately actionable information and eventually allow them to pursue therapeutic remedies at the time of diagnosis. This convergence of access, diagnosis and treatment during one procedure is expected to improve patient experiences and outcomes, improve the efficiency of care and provide important savings to the healthcare system. Headquartered in Cambridge, Mass., NinePoint is backed by Third Rock Ventures and Prospect Venture Partners. | $33M / Series A / Oct 14, 2010 | ||
| Portola Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics for acute and chronic cardiovascular and autoimmune/inflammatory diseases. The company's products include PRT054021, an oral factor Xa inhibitor for the prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedicsurgery; for stroke prevention in patients with atrial fibrillation; and for secondary prevention of myocardial infarction and stroke. Its products also include PRT060128, an oral and intravenous ADP receptor antagonist for the treatment of patients with acute coronary syndrome; for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention; and for secondary prevention of myocardial infarction and stroke. In addition, the company's products include PRT062607, an oral Syk-specific kinase inhibitor for treating chronic inflammatory diseases and Rheumatoid Arthritis (RA) which is used to treat certain cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Portola Pharmaceuticals, Inc. was founded in 2003 and is based in South San Francisco, California. | $60.1M / Series C / Jul 09, 2008 | ||
| Portola Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics for acute and chronic cardiovascular and autoimmune/inflammatory diseases. The company's products include PRT054021, an oral factor Xa inhibitor for the prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedicsurgery; for stroke prevention in patients with atrial fibrillation; and for secondary prevention of myocardial infarction and stroke. Its products also include PRT060128, an oral and intravenous ADP receptor antagonist for the treatment of patients with acute coronary syndrome; for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention; and for secondary prevention of myocardial infarction and stroke. In addition, the company's products include PRT062607, an oral Syk-specific kinase inhibitor for treating chronic inflammatory diseases and Rheumatoid Arthritis (RA) which is used to treat certain cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Portola Pharmaceuticals, Inc. was founded in 2003 and is based in South San Francisco, California. | $21M / Series A / Dec 10, 2003 | ||
| eScout is a web-based e-commerce and e-business network for America's independent businesses and banks. They empower businesses through a group of online services so they can buy, sell, learn and grow. | $25M / Mar 01, 2000 | ||
| See all 11 investments → | |||
Co-Investors
Prospect Venture Partners is a venture capital firm with over $1B of capital under management. The firm is dedicated to investing in outstanding biopharmaceutical and medical device companies. Prospect targets commercially attractive biomedical enterprises with outstanding entrepreneurial management teams, proprietary products, and innovativetechnologies with the potential for significant investment returns. The firm invests in companies with a wide variety of development and financing requirements including new company incubations, first and second venture financing rounds, and later stage private and public companies with proven business models requiring expansion capital.
Prospect Venture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David Schnell
Managing Director
|
|||
Russell Hirsch
Managing Director
|
|||
|
Russell Hirsch
Managing Director
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Russell Hirsch invest in?
Russell Hirsch invests primarily in Health Care, Medical and Software startups, most often at Seed and Series A stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Russell Hirsch's check size?
Russell Hirsch typically joins rounds of $7.3M–$33M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Russell Hirsch participates in.
How do I contact Russell Hirsch?
Public channels for Russell Hirsch include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Russell Hirsch last invest?
The most recent investment recorded for Russell Hirsch closed in Jun 2022. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
